---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-26-000046"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2026-06-15T13:21:02+00:00"
generated_at: "2026-06-15T13:22:10.717921+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elicio Phase 2 AMPLIFY-7P misses primary DFS endpoint; positive R0 subgroup guides Phase 3

## Summary
- AMPLIFY-7P did not meet primary endpoint of DFS in ITT; R1 resection imbalance (19% vs 10%) favored observation arm.
- Post-hoc analysis in R0 patients showed HR 0.65 (p=0.048); mDFS 23.8 mo vs 12.8 mo; 84% of study population.
- mKRAS-specific T cell responses strongly correlated with DFS (HR 0.22, p<0.0001, n=90).
- Refined Phase 3 plan targets R0 resected patients with additional dosing; cash runway into Q4 2026; exploring financing.
- Favorable safety: no treatment-related discontinuations or deaths.

## SEC filing metadata
- accession: 0001601485-26-000046
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2026-06-15T13:21:02+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000046/0001601485-26-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000046/angn-20260615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-26-000046
- JSON: https://secwatch.observer/filing/0001601485-26-000046.json
- Plain text: https://secwatch.observer/filing/0001601485-26-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.